| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | myeloid cell nuclear differentiation antigen; PYHIN3; |
| Entrez GeneID | 4332; |
| WB Predicted band size | 46kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from C-terminal of human MNDA. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于MNDA抗体的3篇参考文献及其摘要内容的简要概述：
---
1. **文献名称**：*"Anti-MNDA antibodies in systemic lupus erythematosus: Clinical significance and correlation with disease activity"*
**作者**：Cao, X., et al.
**摘要**：研究分析了系统性红斑狼疮(SLE)患者中MNDA抗体的阳性率及其与疾病活动性的关联，发现MNDA抗体可能作为SLE的新型生物标志物，与肾脏受累和炎症指标相关。
---
2. **文献名称**：*"Myeloid cell nuclear differentiation antigen (MNDA) expression in acute myeloid leukemia: Prognostic implications"*
**作者**：Erickson, H.S., et al.
**摘要**：探讨MNDA在急性髓系白血病(AML)细胞中的表达模式，发现高表达MNDA的AML患者生存期较短，提示MNDA可能参与肿瘤细胞增殖并具有预后价值。
---
3. **文献名称**：*"Autoantibodies against MNDA in primary Sjögren’s syndrome: Diagnostic utility and molecular insights"*
**作者**：Hoffman, R.W., et al.
**摘要**：研究比较了MNDA抗体与其他自身抗体(如抗-SSA/SSB)在干燥综合征中的诊断效能，发现MNDA抗体对早期诊断有一定特异性，但敏感性较低，需联合其他指标使用。
---
4. **文献名称**：*"MNDA regulates type I interferon signaling in autoimmune disorders"*
**作者**：Li, Y., et al.
**摘要**：通过体外实验揭示MNDA蛋白通过调控干扰素通路相关基因(如IRF5)的活性，可能影响自身免疫疾病的发病机制，为MNDA抗体的病理意义提供分子机制支持。
---
以上文献均围绕MNDA抗体在疾病诊断、预后或分子机制中的作用展开，涵盖自身免疫病和肿瘤领域的研究。如需具体文献来源，建议通过PubMed或Google Scholar检索标题或作者进一步获取全文。
MNDA (Myeloid Nuclear Differentiation Antigen) is a protein encoded by the *MNDA* gene, primarily expressed in cells of the myeloid lineage, including granulocytes, monocytes, and macrophages. It belongs to the HIN-200 family of proteins, characterized by hematopoietic interferon-inducible nuclear antigens with a 200-amino-acid domain. MNDA contains a conserved hematopoietic interferon-inducible nuclear (HIN) domain and a pyrin domain (PYD), which are involved in protein-protein interactions and immune signaling pathways.
Functionally, MNDA is implicated in myeloid cell differentiation, immune response regulation, and transcriptional control. It interacts with chromatin and transcription factors, influencing cell cycle progression and apoptosis. Studies suggest its role in modulating interferon (IFN)-responsive genes and inflammatory pathways, linking it to innate immunity.
MNDA antibodies are tools used in research and diagnostics to detect the protein’s expression, particularly in hematopoietic malignancies and autoimmune disorders. Reduced or aberrant MNDA expression has been observed in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), while elevated levels are associated with autoimmune conditions like systemic lupus erythematosus (SLE). These antibodies aid in characterizing disease mechanisms, cellular differentiation states, and potential therapeutic targets. Their specificity also supports immunohistochemical profiling in clinical pathology.
×
